Frank Reed

A routine filing from wealth manager Rathbones reveals its 7.01% stake in Idox Plc, putting a spotlight on the software firm's acquisition and its future.

Hedge fund Balyasny Asset Management reveals a major stake in the Unite-Empiric takeover, signaling a high-stakes arbitrage play amid regulatory scrutiny.

A last-minute regulatory filing by Balyasny Asset Management pulls back the curtain on the multi-billion-dollar battle for Spectris, a key health tech enabler.

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.

A routine financial disclosure from an asset manager unveils Qualcomm's $2.4B bet on Alphawave, signaling a major push into the AI infrastructure that powers health tech.

A regulatory filing reveals Balyasny Asset Management's strategic trading in Just Group as the stock hits a 52-week high during a takeover.

A routine regulatory filing by hedge fund Balyasny pulls back the curtain on a multi-billion dollar bidding war for Avadel Pharmaceuticals. Here's why.

A hedge fund's regulatory filing for Unite Group reveals a complex strategy, offering a rare glimpse into the high-stakes UK student housing market.

A hedge fund's complex play in a $2.4B tech takeover reveals the hidden hardware foundation that will power the next generation of AI diagnostics.

A tiny share sale by investment giant Rathbones reveals subtle strategies and institutional chess moves in the high-stakes takeover battle for Unite Group.

A regulatory filing reveals Balyasny's stake in Avadel Pharmaceuticals, exposing the high-stakes financial chess game behind a major narcolepsy drug.

A hedge fund's 2.26% derivative stake in Spectris plc pulls back the curtain on the complex financial strategies driving the high-value world of tech M&A.

A UK tech firm's takeover reveals a Wall Street play and the silicon foundation for the next generation of AI diagnostics and personalized medicine.

A UK regulatory filing has peeled back the curtain on Qualcomm's big bet on Alphawave IP, revealing the high-stakes battle for the tech that will power AI medicine.

Behind complex financial maneuvers lies Qualcomm's strategy to dominate health tech's infrastructure. Is the chip giant's M&A spree a bet on our medical future?

A hedge fund's move on Spectris plc reveals a quiet battle for the precision instruments that power the future of medicine and life sciences.

A mandatory disclosure shows asset manager Rathbones trimming its stake in Empiric Student Property, offering a glimpse into institutional strategy.

A $2.4B semiconductor deal seems far from medicine. Yet, Qualcomm's acquisition of Alphawave is building the digital nervous system for AI diagnostics.

A $2.4B bid for a UK chip designer reveals the fierce M&A war for the silicon that will power the future of AI diagnostics and precision medicine.

Hedge fund Balyasny reveals a 1.25% stake in Empiric Student Property amid a major merger, signaling a calculated move in a red-hot market.